Verastem, Inc.

NasdaqCM:VSTM Stock Report

Market Cap: US$660.7m

Verastem Future Growth

Future criteria checks 2/6

Verastem is forecast to grow earnings and revenue by 41.7% and 37.8% per annum respectively while EPS is expected to grow by 49.5% per annum.

Key information

41.7%

Earnings growth rate

49.54%

EPS growth rate

Biotechs earnings growth27.2%
Revenue growth rate37.8%
Future return on equityn/a
Analyst coverage

Good

Last updated10 Aug 2026

Recent future growth updates

Analysis Article • May 11

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

It's been a sad week for Verastem, Inc. ( NASDAQ:VSTM ), who've watched their investment drop 18% to US$4.89 in the...

Recent updates

Narrative Update • Aug 10

VSTM: TARGET-D Trials Will Shape Future Upside In Crowded KRAS Space

Verastem's analyst fair value estimate has moved from $20.00 to $18.00 as analysts recalibrate their models and lower price targets in light of recent Q1 and Q2 updates and a more crowded competitive field. Analyst Commentary Recent Street research on Verastem shows a cluster of lower price targets following Q1 and Q2 updates, yet many bullish analysts are maintaining positive views on the stock.
Narrative Update • Jun 26

VSTM: Future KRAS Data And Pancreatic Trial Progress Will Drive Repricing

The Verastem analyst price target has been revised lower, with a fair value estimate moving from about $14.00 to about $8.85 as analysts factor in a less favorable long thesis in a more crowded competitive space and updated post-earnings models. Analyst Commentary on Verastem Recent Street research on Verastem reflects a more cautious tone, with several bearish analysts trimming their fair value assumptions and reassessing the long thesis after recent earnings and competitive updates.
Analysis Article • May 11

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

It's been a sad week for Verastem, Inc. ( NASDAQ:VSTM ), who've watched their investment drop 18% to US$4.89 in the...
New Narrative • Jan 22

RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential

Catalysts About Verastem Verastem is an oncology company focused on therapies for RAS and MAPK pathway driven cancers, including KRAS mutated recurrent low grade serous ovarian cancer. What are the underlying business or industry changes driving this perspective?
Analysis Article • Dec 26

Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump

Verastem, Inc. ( NASDAQ:VSTM ) shareholders won't be pleased to see that the share price has had a very rough month...
Seeking Alpha • Jul 16

Verastem: The Market Is Ignoring The Progress

Summary FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promising pipeline, including VS-7375 for KRAS G12D, offer significant upside with multiple near-term catalysts ahead. Risks include slow commercial uptake, pipeline uncertainty, and potential future dilution, but current valuation under $5 presents an attractive entry point. I maintain a 3/5 conviction, plan to add to my position below $5.75, and aim to hold long-term as VSTM targets KRAS-driven cancers. Read the full article on Seeking Alpha
Seeking Alpha • May 26

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Summary Verastem's stock plummeted after updates showed reduced efficacy in cancer treatment trials, causing a reassessment of strategy. Updated clinical trial results show a significant drop in response rates, suggesting less robust efficacy than earlier believed. Financially, Verastem has only a year of cash runway and faces significant dilution risks to extend it. Downgrade the recommendation to 'hold' due to increased risks and market volatility associated with microcap stocks. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqCM:VSTM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028260-114-98-907
12/31/2027181-157-150-1458
12/31/2026116-166-166-1629
6/30/202688-203-172-162N/A
3/31/202650-194-161-151N/A
12/31/202531-209-147-138N/A
9/30/202513-241-141-133N/A
6/30/20252-167-120-120N/A
3/31/202510-149-115-115N/A
12/31/202410-131-105-105N/A
9/30/202410-93-109-109N/A
6/30/202410-89-102-102N/A
3/31/2024N/A-106-95-94N/A
12/31/2023N/A-87-86-86N/A
9/30/2023N/A-77-73-73N/A
6/30/2023N/A-75-72-72N/A
3/31/2023N/A-73-65-65N/A
12/31/20223-74-64-64N/A
9/30/20223-73-57-57N/A
6/30/20223-78-53-53N/A
3/31/20224-73-53-53N/A
12/31/20212-71-54-54N/A
9/30/20212-75-65-65N/A
6/30/202181-39-10-10N/A
3/31/202184-45-19-19N/A
12/31/202089-68-34-34N/A
9/30/202092-87-49-49N/A
6/30/202022-130-122-122N/A
3/31/202021-149N/A-134N/A
12/31/201917-149N/A-139N/A
9/30/201915-122N/A-120N/A
6/30/201922-113N/A-115N/A
3/31/201928-89N/A-91N/A
12/31/201827-72N/A-75N/A
9/30/201826-79N/A-76N/A
6/30/201810-81N/A-65N/A
3/31/2018N/A-76N/A-69N/A
12/31/2017N/A-68N/A-57N/A
9/30/2017N/A-61N/A-43N/A
6/30/2017N/A-46N/A-37N/A
3/31/2017N/A-41N/A-29N/A
12/31/2016N/A-36N/A-29N/A
9/30/2016N/A-37N/A-34N/A
6/30/2016N/A-44N/A-39N/A
3/31/2016N/A-51N/A-45N/A
12/31/2015N/A-58N/A-46N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VSTM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VSTM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VSTM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VSTM's revenue (37.8% per year) is forecast to grow faster than the US market (12.9% per year).

High Growth Revenue: VSTM's revenue (37.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VSTM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/20 22:30
End of Day Share Price 2026/08/20 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Verastem, Inc. is covered by 29 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew CrossAlliance Global Partners
James MolloyAlliance Global Partners
Matthew VeneziaAlliance Global Partners